首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   348462篇
  免费   21262篇
  国内免费   667篇
耳鼻咽喉   4724篇
儿科学   12182篇
妇产科学   11595篇
基础医学   52859篇
口腔科学   8279篇
临床医学   29243篇
内科学   67701篇
皮肤病学   7477篇
神经病学   26812篇
特种医学   12710篇
外国民族医学   43篇
外科学   50930篇
综合类   8059篇
现状与发展   2篇
一般理论   201篇
预防医学   24853篇
眼科学   7802篇
药学   24881篇
中国医学   921篇
肿瘤学   19117篇
  2021年   4596篇
  2020年   2739篇
  2019年   4004篇
  2018年   5553篇
  2017年   4216篇
  2016年   4789篇
  2015年   5357篇
  2014年   7009篇
  2013年   10253篇
  2012年   13547篇
  2011年   13926篇
  2010年   8495篇
  2009年   7578篇
  2008年   12061篇
  2007年   12904篇
  2006年   12419篇
  2005年   11740篇
  2004年   11244篇
  2003年   10460篇
  2002年   9836篇
  2001年   13554篇
  2000年   13827篇
  1999年   11667篇
  1998年   3356篇
  1997年   3070篇
  1996年   2826篇
  1995年   2727篇
  1992年   8408篇
  1991年   8532篇
  1990年   8323篇
  1989年   8150篇
  1988年   7384篇
  1987年   7134篇
  1986年   6777篇
  1985年   6573篇
  1984年   4843篇
  1983年   4185篇
  1982年   2546篇
  1979年   4456篇
  1978年   3260篇
  1977年   2765篇
  1976年   2528篇
  1975年   2852篇
  1974年   3370篇
  1973年   3380篇
  1972年   3130篇
  1971年   2957篇
  1970年   2845篇
  1969年   2590篇
  1968年   2549篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
Journal of Behavioral Medicine - Evidence supports the use of graphic warnings to educate the public about the health harms of smoking and suggests warnings eliciting negative emotional responses...  相似文献   
3.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF.  相似文献   
4.
Forgiveness has been found one substantial element in the recovery for women survivors from intimate partner violence following the termination of the abusive relationship. To further investigate the details of forgiveness in this specific context, the present study explored the process of forgiveness using grounded theory. In-depth and semi-structured interviews were conducted with 25 Chinese women survivors of IPV. The findings suggest that forgiveness is a strength-based process including empowerment, transformation, and integration phases. In the empowerment phase, survivors obtain strength at the intrapersonal, behavioural, and interpersonal levels. In the transformation phase, survivors complete cognitive transformation for their IPV experiences and emotional transformation towards former partners. In the integration phase, survivors—now freed from the past—reflect upon and apply the changes they have undergone. Two trajectories in the process were found. One trajectory is going through stages sequentially and the other trajectory is experiencing back and forth between empowerment and transformation stages before moving into the integration stage. The study's findings broaden our knowledge of the strength-based forgiveness process that women survivors of IPV undergo during recovery. Practitioners and policymakers could develop programmes and policies that support forgiveness by holistically facilitating their recovery and empowerment like assistance in dealing with life difficulties and promoting their reconnection with social networks. To improve the transferability and validity of the findings, the forgiveness of survivors of IPV could be explored in a diverse sample (e.g., survivors with low educational background or live in the rural area).  相似文献   
5.
6.
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号